Relmada Therapeutics (RLMD)
(Real Time Quote from BATS)
$4.04 USD
-0.12 (-2.89%)
Updated Jul 22, 2024 01:24 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RLMD 4.04 -0.12(-2.89%)
Will RLMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RLMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLMD
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
RLMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Other News for RLMD
Here's What You Missed in Cannabis, Psychedelics This Week
Here's What You Missed in Cannabis, Psychedelics This Week
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Relmada Therapeutics reports published Phase 3 results of REL-1017
Here's What You Missed in Cannabis, Psychedelics This Week